New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
November 6, 2009
08:11 EDTRDEA
theflyonthewall.com: Ardea Biosciences expects to report results from RDEA594-203 in Q1
Barry D. Quart, PharmD, Ardea's president and CEO commented: "We expect to provide results from the second cohort of our ongoing Phase 2a proof-of-concept study evaluating RDEA594 in combination with allopurinol and Study RDEA594-105, along with an update on progress in RDEA594-204, in December 2009. We expect RDEA594-202 to complete enrollment in 2009, with results anticipated in Q1 of 2010. We also expect to report results from RDEA594-203 in Q1 of 2010. :theflyonthewall.com



News For RDEA From The Last 14 Days
Check below for free stories on RDEA the last two weeks.
There are 5 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2012
09:29 EDTRDEA
theflyonthewall.com: Pre-market top 5 losers

Subscribe for More Information :theflyonthewall.com
08:52 EDTRDEA
theflyonthewall.com: Ardea Biosciences slips on secondary, support is at $16.90
:theflyonthewall.com
08:44 EDTRDEA
theflyonthewall.com: Ardea Biosciences 8.5M share Spot Secondary priced at $17.00
Jefferies acted as lead book running manager for the offering. :theflyonthewall.com

January 31, 2012
16:03 EDTRDEA
theflyonthewall.com: Ardea Biosciences files to sell common stock, no amount given

Subscribe for More Information :theflyonthewall.com
11:21 EDTRDEA
theflyonthewall.com: Piper Jaffray's biotech and specialty pharma analysts hold a conference call

Subscribe for More Information :theflyonthewall.com